These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 29243585)
1. Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma. Alexander N; Vali R; Ahmadzadehfar H; Shammas A; Baruchel S Curr Radiopharm; 2018; 11(1):14-21. PubMed ID: 29243585 [TBL] [Abstract][Full Text] [Related]
2. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma. Kong G; Hofman MS; Murray WK; Wilson S; Wood P; Downie P; Super L; Hogg A; Eu P; Hicks RJ J Pediatr Hematol Oncol; 2016 Mar; 38(2):87-96. PubMed ID: 26296147 [TBL] [Abstract][Full Text] [Related]
3. Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma. Fathpour G; Jafari E; Hashemi A; Dadgar H; Shahriari M; Zareifar S; Jenabzade AR; Vali R; Ahmadzadehfar H; Assadi M Clin Nucl Med; 2021 Jul; 46(7):540-548. PubMed ID: 33782280 [TBL] [Abstract][Full Text] [Related]
4. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Kroiss A; Putzer D; Uprimny C; Decristoforo C; Gabriel M; Santner W; Kranewitter C; Warwitz B; Waitz D; Kendler D; Virgolini IJ Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352 [TBL] [Abstract][Full Text] [Related]
5. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Gains JE; Aldridge MD; Mattoli MV; Bomanji JB; Biassoni L; Shankar A; Gaze MN Nucl Med Commun; 2020 Nov; 41(11):1169-1177. PubMed ID: 32796449 [TBL] [Abstract][Full Text] [Related]
9. Pediatric applications of Dotatate: early diagnostic and therapeutic experience. McElroy KM; Binkovitz LA; Trout AT; Czachowski MR; Seghers VJ; Lteif AN; States LJ Pediatr Radiol; 2020 Jun; 50(7):882-897. PubMed ID: 32495176 [TBL] [Abstract][Full Text] [Related]
10. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222 [TBL] [Abstract][Full Text] [Related]
11. PET/CT imaging in neuroblastoma. Piccardo A; Lopci E; Conte M; Foppiani L; Garaventa A; Cabria M; Villavecchia G; Fanti S; Cistaro A Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):29-39. PubMed ID: 23474633 [TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Win Z; Al-Nahhas A; Towey D; Todd JF; Rubello D; Lewington V; Gishen P Nucl Med Commun; 2007 May; 28(5):359-63. PubMed ID: 17414885 [TBL] [Abstract][Full Text] [Related]
13. Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides? Briganti V; Cuccurullo V; Di Stasio GD; Mansi L Curr Radiopharm; 2019; 12(2):156-170. PubMed ID: 30827276 [TBL] [Abstract][Full Text] [Related]
14. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215 [TBL] [Abstract][Full Text] [Related]
17. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704 [TBL] [Abstract][Full Text] [Related]
18. The Complementary Role of 68Ga-DOTATATE PET/CT in Neuroblastoma. Telli T; Lay Ergün E; Volkan Salanci B; Özgen Kiratli P Clin Nucl Med; 2020 Apr; 45(4):326-329. PubMed ID: 31977455 [TBL] [Abstract][Full Text] [Related]
19. Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy. Makis W; McCann K; Bryanton M; McEwan AJ Clin Nucl Med; 2015 Dec; 40(12):962-4. PubMed ID: 26359563 [TBL] [Abstract][Full Text] [Related]
20. Selective use of Peptide Receptor Radionuclide Therapy following comparative imaging of Ga-68 DOTATATE PET/CT against I-131 MIBG scintigraphy in a small Asian cohort of Adult Neuroblastoma. Koo SX; Tong AK; Soh SY; Farid M; Loh A; Loke KS Med J Malaysia; 2021 Jul; 76(4):573-577. PubMed ID: 34305122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]